MiR675-5p Acts on HIF-1α to Sustain Hypoxic Responses: A New Therapeutic Strategy for Glioma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This study introduces an innovative magnetic-based multifunctional anti-cancer drug carrier aiming to enhance the efficacy of curcumin in cancer therapy.The research investigates the potential of Graphene Quantum Dots (GQDs) as a curcumin drug delivery system for inhibiting in vivo cancer growth.GQDs with a particle diameter below 10 nm were synthesized via hydrothermal and Hummers methods, exhibiting homogeneity and crystalline structure according to AFM and XRD analyses.FTIR analysis confirmed functionalization success, revealing the formation of bonds between GQDs and curcumin.The optical properties of GQDs were assessed using a UV-Vis spectrophotometer and spectrofluorometer, resulting in vigorous fluorescence with a quantum yield of 1.32%.Subsequently, loading curcumin onto GQDs (CQDs/cur) resulted in an efficient system for delivering the anti-cancer drug, demonstrating significant in vivo efficacy.It was indicated by reduced tumor diameter and increased body weight in mice.Furthermore, the release kinetics of curcumin from GQDs were analyzed using the Peppas-Sahlin equation under varying pH conditions (4, 7, and 9), revealing the highest release rate in acidic conditions.In conclusion, this study highlights the potential of GQDs as highly efficient carriers for targeted curcumin delivery, showcasing promising prospects in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 1×
“Interestingly, the vast majority of hypoxia-induced microRNAs are also overexpressed in a variety of human tumours [40].”
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990 · cited 1×
“Like VEGF, HIF-1α is able to activate a multitude of downstream genes involved in survival and proliferation (IGF-2, TGF-α, NOTCH-1), invasiveness (CXCR-4, MMP), new vessels formation (VEGF-A, VEGF-R1, ANGPT-1), metabolic adaptation (GLUT1/3, GAPDH) and pharmacological resistance [9] by binding Hypoxia Responsive Elem…”
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806 · cited 1×
“Hypoxia is a predominant feature in glioma and its microenvironment [35], it is associated with tumour growth, progression and resistance to conventional therapy [36].”
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725 · cited 1×
“Hypoxia is a predominant feature in glioma and its microenvironment [35], it is associated with tumour growth, progression and resistance to conventional therapy [36].”
Liposomal delivery of natural product: A promising approach in health research
Islam Shishir, M. R., Karim, N., Gowd, V., Zheng, X., & Chen, W. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.01.013 · Cited by 178
Hypoxia-regulated microRNAs in human cancer
Shen, G., Li, X., Jia, Y.-F., Piazza, G. A., & Xi, Y. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.195 · Cited by 164 · cited 1×
“When low oxygen induces the expression of HRMs, some genes targeted by these miRNAs stabilize HIF1-α by forming positive-feedback loops: miR-210 could repress glycerol-3-phosphate dehydrogenase 1-like (GPD1L), which, in turn, affects HIF1α stability or miR-424 that, by suppressing cullin2 in human endothelial cells, b…”
Mack, F. A., Rathmell, W. K., Arsham, A. M., Gnarra, J., Keith, B., & Simon, M. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00240-4 · Cited by 160 · cited 3×
“[6], loss of Vhl is sufficient to completely dysregulate HIF-1α and to promote its activity.”
InfluentialAnalysis of extracellular vesicles as emerging theranostic nanoplatforms
Xing, Y., Cheng, Z., Wang, R., Lv, C., James, T. D., & Yu, F. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213506 · Cited by 67
Ünal, S., Can Öztürk, S., Bilgiç, E., Yanık, H., Korkusuz, P., Aktaş, Y., Benito, J. M., Esendağlı, G., & Bilensoy, E. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.010 · Cited by 25
Cited by
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Jiang, Y., Mao, C., Yang, R., Yan, B., Shi, Y., Liu, X., Lai, W., Liu, Y., Wang, X., Xiao, D., et al. (2017) · Theranostics · doi:10.7150/thno.19988 · Cited by 292
Rynkeviciene, R., Simiene, J., Strainiene, E., Stankevicius, V., Usinskiene, J., Miseikyte Kaubriene, E., Meskinyte, I., Cicenas, J., & Suziedelis, K. (2018) · Cancers · doi:10.3390/cancers11010017 · Cited by 136
Regulation of the HIF switch in human endothelial and cancer cells
Slawski, J., Jaśkiewicz, M., Barton, A., Kozioł, S., Collawn, J. F., & Bartoszewski, R. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151386 · Cited by 26
Metadata
- Authors
- Lo Dico, A., Costa, V., Martelli, C., Diceglie, C., Rajata, F., Rizzo, A., Mancone, C., Tripodi, M., Ottobrini, L., Alessandro, R., & Conigliaro, A.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2016
- Volume
- 6
- Issue
- 8
- Pages
- 1105-1118
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2402984081
- Cited by
- 49
- References
- 10
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.